Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Liabilities (2016 - 2025)

Lexaria Bioscience's Total Liabilities history spans 11 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 282.11% year-over-year to $1.5 million; the TTM value through Nov 2025 reached $1.5 million, up 282.11%, while the annual FY2025 figure was $1.6 million, 30.08% up from the prior year.
  • Total Liabilities for Q4 2025 was $1.5 million at Lexaria Bioscience, down from $1.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.9 million in Q1 2025 and bottomed at $194623.0 in Q1 2022.
  • The 5-year median for Total Liabilities is $281450.5 (2021), against an average of $644461.7.
  • The largest annual shift saw Total Liabilities crashed 77.36% in 2024 before it surged 838.67% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $277328.0 in 2021, then grew by 1.51% to $281520.0 in 2022, then dropped by 9.76% to $254040.0 in 2023, then surged by 57.34% to $399718.0 in 2024, then skyrocketed by 282.11% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Total Liabilities are $1.5 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).